Clinical Trials Logo
  1. Home
  2. Acute Leukemia
  3. NCT01385891

Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children — CLOVE  

Acute Leukemia Clinical Trial

Official title:
Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients

Clinical Trial Summary

Study Hypothesis. combination chemotherapy with Clofarabine VP16 and Cyclophosphamide is able to induce remission in resistant/refractory acute leukemias in pediatric.

Forty children with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) entered the study and received the association of clofarabine (40 mg/m2/day) in combination with etoposide (100 mg/m2/day) and Cyclophosphamide (440 mg/m2/day) in 1 or 2 induction cycles End point were complete remission (CR)or CR without platelet recovery (CRp) and toxicity

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01385891
Study type Interventional
Source Istituto Giannina Gaslini
Contact
Status Completed
Phase Phase 2/Phase 3
Start date August 2008
Completion date February 2010
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT01956630 - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Phase 1/Phase 2
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Active, not recruiting NCT03595800 - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Phase 3
Completed NCT02440178 - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Phase 2
Recruiting NCT05071482 - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Phase 4
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Terminated NCT03588936 - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Phase 1
Recruiting NCT05521204 - Olverembatinib for FGFR1-rearranged Neoplasms Phase 2
Not yet recruiting NCT04084327 - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors